Literature DB >> 30445007

NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice.

Shuang Liang1, Hsiao-Yen Ma1, Zhenyu Zhong2, Debanjan Dhar2, Xiao Liu1, Jun Xu1, Yukinori Koyama3, Takahiro Nishio3, Daniel Karin1, Gabriel Karin1, Ryan Mccubbin1, Cuili Zhang4, Ronglin Hu5, Guizhi Yang6, Li Chen1, Souradipta Ganguly1, Tian Lan6, Michael Karin2, Tatiana Kisseleva7, David A Brenner8.   

Abstract

BACKGROUND & AIMS: Although there are associations among oxidative stress, reduced nicotinamide adenine dinucleotide phosphate oxidase (NOX) activation, and hepatocellular carcinoma (HCC) development, it is not clear how NOX contributes to hepatocarcinogenesis. We studied the functions of different NOX proteins in mice after administration of a liver carcinogen.
METHODS: Fourteen-day-old Nox1-/- mice, Nox4-/- mice, Nox1-/-Nox4-/- (double-knockout) mice, and wild-type (WT) C57BL/6 mice were given a single intraperitoneal injection of diethylnitrosamine (DEN) and liver tumors were examined at 9 months. We also studied the effects of DEN in mice with disruption of Nox1 specifically in hepatocytes (Nox1ΔHep), hepatic stellate cells (Nox1ΔHep), or macrophages (Nox1ΔMac). Some mice were also given injections of the NOX1-specific inhibitor ML171. To study the acute effects of DEN, 8-12-week-old mice were given a single intraperitoneal injection, and liver and serum were collected at 72 hours. Liver tissues were analyzed by histologic examination, quantitative polymerase chain reaction, and immunoblots. Hepatocytes and macrophages were isolated from WT and knockout mice and analyzed by immunoblots.
RESULTS: Nox4-/- mice and WT mice developed liver tumors within 9 months after administration of DEN, whereas Nox1-/- mice developed 80% fewer tumors, which were 50% smaller than those of WT mice. Nox1ΔHep and Nox1ΔHSC mice developed liver tumors of the same number and size as WT mice, whereas Nox1ΔMac developed fewer and smaller tumors, similar to Nox1-/- mice. After DEN injection, levels of tumor necrosis factor, interleukin 6 (IL6), and phosphorylated signal transducer and activator of transcription 3 were increased in livers from WT, but not Nox1-/- or Nox1ΔMac, mice. Conditioned medium from necrotic hepatocytes induced expression of NOX1 in cultured macrophages, followed by expression of tumor necrosis factor, IL6, and other inflammatory cytokines; this medium did not induce expression of IL6 or cytokines in Nox1ΔMac macrophages. WT mice given DEN followed by ML171 developed fewer and smaller liver tumors than mice given DEN followed by vehicle.
CONCLUSIONS: In mice given injections of a liver carcinogen (DEN), expression of NOX1 by macrophages promotes hepatic tumorigenesis by inducing the production of inflammatory cytokines. We propose that upon liver injury, damage-associated molecular patterns released from dying hepatocytes activate liver macrophages to produce cytokines that promote tumor development. Strategies to block NOX1 or these cytokines might be developed to slow hepatocellular carcinoma progression.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Inflammation; Macrophage; Reactive oxygen species

Mesh:

Substances:

Year:  2018        PMID: 30445007      PMCID: PMC6409207          DOI: 10.1053/j.gastro.2018.11.019

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  69 in total

Review 1.  Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome.

Authors:  Inna S Afonina; Zhenyu Zhong; Michael Karin; Rudi Beyaert
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

Review 2.  Advances in targeted therapies for hepatocellular carcinoma in the genomic era.

Authors:  Josep M Llovet; Augusto Villanueva; Anja Lachenmayer; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2015-06-09       Impact factor: 66.675

3.  Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis.

Authors:  Samuele De Minicis; Ekihiro Seki; Yong-Han Paik; Christoph H Osterreicher; Yuzo Kodama; Johannes Kluwe; Luciano Torozzi; Katsumi Miyai; Antonio Benedetti; Robert F Schwabe; David A Brenner
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

Review 4.  Reparative inflammation takes charge of tissue regeneration.

Authors:  Michael Karin; Hans Clevers
Journal:  Nature       Date:  2016-01-21       Impact factor: 49.962

5.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

Review 6.  Obesity-associated mechanisms of hepatocarcinogenesis.

Authors:  Raffi Karagozian; Zoltán Derdák; György Baffy
Journal:  Metabolism       Date:  2014-02-05       Impact factor: 8.694

7.  The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma.

Authors:  J Polesel; A Zucchetto; M Montella; L Dal Maso; A Crispo; C La Vecchia; D Serraino; S Franceschi; R Talamini
Journal:  Ann Oncol       Date:  2008-08-22       Impact factor: 32.976

8.  Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study.

Authors:  Dimitrios Trichopoulos; Christina Bamia; Pagona Lagiou; Veronika Fedirko; Elisabeth Trepo; Mazda Jenab; Tobias Pischon; Ute Nöthlings; Kim Overved; Anne Tjønneland; Malene Outzen; Francoise Clavel-Chapelon; Rudolf Kaaks; Annekatrin Lukanova; Heiner Boeing; Krasimira Aleksandrova; Vassiliki Benetou; Dimosthenis Zylis; Domenico Palli; Valeria Pala; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; H Bas Bueno-De-Mesquita; Henk J Van Kranen; Petra H M Peeters; Eiliv Lund; J Ramón Quirós; Carlos A González; Maria-Jose Sanchez Perez; Carmen Navarro; Miren Dorronsoro; Aurelio Barricarte; Björn Lindkvist; Sara Regnér; Mårten Werner; Göran Hallmans; Kay-Tee Khaw; Nick Wareham; Timothy Key; Isabelle Romieu; Shu-Chun Chuang; Neil Murphy; Paolo Boffetta; Antonia Trichopoulou; Elio Riboli
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506

9.  Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism.

Authors:  Sarah Garrido-Urbani; Stephane Jemelin; Christine Deffert; Stéphanie Carnesecchi; Olivier Basset; Cédric Szyndralewiez; Freddy Heitz; Patrick Page; Xavier Montet; Liliane Michalik; Jack Arbiser; Curzio Rüegg; Karl Heinz Krause; Beat A Imhof; Beat Imhof
Journal:  PLoS One       Date:  2011-02-07       Impact factor: 3.240

10.  Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.

Authors:  Christine C Hsu; Juliane S Troeger; Ingmar Mederacke; Peter Huebener; Xueru Mu; Dianne H Dapito; Jean-Philippe Pradere; Robert F Schwabe
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  22 in total

1.  Inhibiting the Activity of NADPH Oxidase in Cancer.

Authors:  Mariam M Konaté; Smitha Antony; James H Doroshow
Journal:  Antioxid Redox Signal       Date:  2020-04-17       Impact factor: 8.401

2.  Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients.

Authors:  Jing Chen; Dan-Xue Zheng; Xing-Juan Yu; Hong-Wei Sun; Yi-Tuo Xu; Yao-Jun Zhang; Jing Xu
Journal:  Oncoimmunology       Date:  2019-08-15       Impact factor: 8.110

Review 3.  Nox1 downregulators: A new class of therapeutics.

Authors:  Matthias Barton; Matthias R Meyer; Eric R Prossnitz
Journal:  Steroids       Date:  2019-09-10       Impact factor: 2.668

Review 4.  Mechanisms of liver fibrosis and its role in liver cancer.

Authors:  Debanjan Dhar; Jacopo Baglieri; Tatiana Kisseleva; David A Brenner
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-10

Review 5.  Antioxidant Therapy in Cancer: Rationale and Progress.

Authors:  Maochao Luo; Li Zhou; Zhao Huang; Bowen Li; Edouard C Nice; Jia Xu; Canhua Huang
Journal:  Antioxidants (Basel)       Date:  2022-06-08

6.  A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma.

Authors:  Qian Yan; Wenjiang Zheng; Boqing Wang; Baoqian Ye; Huiyan Luo; Xinqian Yang; Ping Zhang; Xiongwen Wang
Journal:  BioData Min       Date:  2021-05-07       Impact factor: 2.522

7.  IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.

Authors:  Hsiao-Yen Ma; Gen Yamamoto; Jun Xu; Xiao Liu; Daniel Karin; Ju Youn Kim; Ludmil B Alexandrov; Yukinori Koyama; Takahiro Nishio; Chris Benner; Sven Heinz; Sara B Rosenthal; Shuang Liang; Mengxi Sun; Gabriel Karin; Peng Zhao; Pnina Brodt; Iain H Mckillop; Oswald Quehenberger; Ed Dennis; Alan Saltiel; Hidekazu Tsukamoto; Bin Gao; Michael Karin; David A Brenner; Tatiana Kisseleva
Journal:  J Hepatol       Date:  2019-12-31       Impact factor: 25.083

Review 8.  From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.

Authors:  Peng Zhao; Alan R Saltiel
Journal:  J Biol Chem       Date:  2020-07-10       Impact factor: 5.157

9.  Single-Dose Toxicity Study on ML171, a Selective NOX1 Inhibitor, in Mice.

Authors:  Se-Hyun Oh; Ji-Sun Ahn; Eun-Joo Oh; You-Jin Kim; Ju-Min Yook; Jeong-Hoon Lim; Hee-Yeon Jung; Ji-Young Choi; Chan-Duck Kim; Sun-Hee Park; Yong-Lim Kim; Jang-Hee Cho
Journal:  Biomed Res Int       Date:  2021-05-30       Impact factor: 3.411

10.  Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Is Associated with Increased Intestinal Inflammation.

Authors:  Destiny R Matthews; Honggui Li; Jing Zhou; Qingsheng Li; Shannon Glaser; Heather Francis; Gianfranco Alpini; Chaodong Wu
Journal:  Am J Pathol       Date:  2021-07-07       Impact factor: 5.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.